280Bio Inc. has divulged compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.

Scientists at Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have described GTPase KRAS and/or its mutant inhibitors reported to be useful for the treatment of cancer.

Revolution Medicines Inc. has synthesized macrocyclic compounds acting as GTPase KRAS, NRAS, HRAS and their mutant inhibitors reported to be useful for the treatment of cancer.

Guangdong HEC Pharmaceutical Co. Ltd. has reported compounds acting as GTPase KRAS and mutant inhibitors and thus reported to be useful for the treatment of cancer.

Eli Lilly & Co. has divulged GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.

Alterome Therapeutics Inc. has synthesized GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Researchers at Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. (dba Bridgebio Oncology Therapeutics) have described GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Suzhou Zion Pharma Technology Co. Ltd. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.

Researchers at Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. have divulged GTPase KRAS inhibitors reported to be useful for the treatment of cancer.